The Technical Analyst
PMV Pharmaceuticals, Inc. [PMVP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
PMV Pharmaceuticals, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.34% $1.750
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 90.03 mill |
| EPS: | -1.440 |
| P/E: | -1.220 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 51.44 mill |
| Avg Daily Volume: | 0.571 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.220 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.21x |
| Company: PE -1.220 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.526 (-69.96%) $-1.224 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.630 - 1.870 ( +/- 6.86%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-18 | Jalota Deepika | Buy | 225 095 | Employee Stock Option (right to buy) |
| 2024-01-18 | Jalota Deepika | Buy | 95 555 | Common Stock |
| 2024-01-18 | Carulli Michael | Buy | 204 630 | Employee Stock Option (right to buy) |
| 2024-01-18 | Carulli Michael | Buy | 82 220 | Common Stock |
| 2024-01-18 | Mack David Henry | Buy | 519 915 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 60.25 |
| Last 97 transactions |
| Buy: 3 540 873 | Sell: 1 925 887 |
Forecast:
16:00 - $1.750
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.750
Forecast 2: 16:00 - $1.750
Forecast 3: 16:00 - $1.750
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.750 (2.34% ) |
| Volume | 0.334 mill |
| Avg. Vol. | 0.571 mill |
| % of Avg. Vol | 58.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PMVP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PMVP
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Last 10 Buy Signals
Latest Press Releases
2024-03-27 08:00:00 - Press Release
Pmv Pharmaceuticals Announces First Patient Dosed In Global Tumor-agnostic Phase 2 Pynnacle Trial For Rezatapopt In Tp53 Y220c-positive Solid Tumors
Princeton, n.j., march 27, 2024 (globe newswire) -- pmv pharmaceuticals, inc. (nasdaq: pmvp), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that the first patient has been dosed in the registrational, tumor-agnostic pynnacle phase 2 trial of rezatapopt (pc14586) in patients with advanced solid tumors harboring a tp53 y220c mutation and kras wild-type (wt). rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets mutated p53 y220c proteins in solid tumors.
2024-03-18 16:01:00 - Press Release
Pmv Pharmaceuticals Pynnacle Phase I Data Of Rezatapopt In Advanced Ovarian Cancer Featured In Late-breaking Oral Presentation At 2024 Sgo Annual Meeting On Women's Cancer
Princeton, n.j., march 18, 2024 (globe newswire) -- pmv pharmaceuticals, inc. (nasdaq: pmvp), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that a phase 1 analysis reported promising anti-tumor activity of rezatapopt (pc14586) in heavily pre-treated patients with advanced ovarian cancer harboring a tp53 y220c mutation. rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets the tp53 y220c mutation in solid tumors.
2024-02-29 16:01:00 - Press Release
Pmv Pharmaceuticals Reports Full Year 2023 Financial Results And Corporate Highlights
Princeton, n.j., feb. 29, 2024 (globe newswire) -- pmv pharmaceuticals, inc. (nasdaq: pmvp), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update.
2024-01-18 16:01:00 - Press Release
Pmv Pharmaceuticals Announces Prioritization Of Pc14586 Clinical Development And Extended Cash Runway
Princeton, n.j., jan. 18, 2024 (globe newswire) -- pmv pharmaceuticals, inc. (nasdaq: pmvp), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced a strategic reduction of its workforce by approximately 30%. pmv will maintain a focused discovery research effort and expects that the resulting savings in operating expenses will extend its cash runway to the end of 2026.
2024-01-05 16:01:00 - Press Release
Pmv Pharmaceuticals Strengthens Leadership With Key Appointments As Company Advances Into Late-stage Development
Princeton, n.j., jan. 05, 2024 (globe newswire) -- pmv pharmaceuticals, inc. (nasdaq: pmvp), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced key appointments across its leadership team. these include:
Latest News
2023-10-16 11:18:36 - Zacks Investment Research
PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for PMV Pharmaceuticals, Inc. (PMVP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-10-11 12:00:00 - GlobeNewsWire
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will present updated Phase 1 data from the ongoing Phase 1/2 PYNNACLE study of PC14586 in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston, Massachusetts. The poster will contain updated clinical data from the study as of September 5, 2023.
2023-09-20 16:05:00 - GlobeNewsWire
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that updated Phase 1 clinical data from its ongoing Phase 1/2 PYNNACLE study of PC14586 will be presented in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 11-15, 2023, in Boston, Massachusetts.
2023-08-30 11:16:21 - Zacks Investment Research
Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 182.6% in PMV Pharmaceuticals, Inc. (PMVP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-06-06 16:01:00 - GlobeNewsWire
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference taking place in Dana Point, California June 12-15, 2023. The company will also be available to meet one-on-one with institutional investors at the conference. Details on the fireside chat can be found below.
2022-11-30 11:18:05 - Finbold
Top 10 most-shorted stocks as of November 2022
The difficult state of the macroeconomic environment in 2022 has had a negative impact on the performance of a number of equity investments. Worries about a recession and a bearish attitude among investors have been especially unsettling for companies with weak financial positions.
2022-10-11 13:32:27 - Zacks Investment Research
PMV Pharmaceuticals, Inc. (PMVP) Upgraded to Buy: Here's What You Should Know
PMV Pharmaceuticals, Inc. (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-06-08 08:00:00 - GlobeNewsWire
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
CRANBURY, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference taking place in Ranchos Palos Verdes, California June 14-16, 2022.
2022-06-07 13:00:44 - InvestorPlace
Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday
We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday appeared first on InvestorPlace.
2022-04-27 10:30:00 - GlobeNewsWire
PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
CRANBURY, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that initial clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 study evaluating PC14586 have been selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place June 3-7, in Chicago, Illinois.